GlassScriptPhysician profile
Gabrielle Davis
NPI 1326642141
$1,817.27
in general payments reported to CMS, 2019-2025
23 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $736 · 2023: $642 · 2024: $249 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.09 |
| Education | $184.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $353.01 | 2022-2025 | |
| Astellas Pharma US INC | $305.09 | 2023-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $245.26 | 2022-2023 | |
| Exeltis, USA INC. | $179.13 | 2022-2025 | Slynd |
| Medical Device Business Services, INC. | $109.93 | 2022 | |
| Hologic Sales and Service, LLC | $109.13 | 2022-2025 | Novasure, Acessa Provu System, Aptima |
| Sumitomo Pharma America, INC. | $70.47 | 2023-2024 | Myfembree, Gemtesa |
| Amgen INC. | $67.17 | 2022-2025 | Evenity, Prolia |
| Agile Therapeutics, INC. | $56.55 | 2022 | |
| Novo Nordisk INC | $40.11 | 2023 | Wegovy |
| Exact Sciences Corporation | $34.70 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $32.65 | 2023-2024 | Gardasil 9, Gardasil |
| Biohaven Pharmaceutical Holding Company LTD. | $31.52 | 2022 | |
| Organon LLC | $30.27 | 2022-2024 | |
| Boston Scientific Corporation | $28.27 | 2025 | Bodyguardian |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.51 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.04 | 2022 | |
| Millicent US INC | $15.81 | 2025 | Intrarosa |
| Myovant Sciences INC. | $15.50 | 2022 | |
| Pharmacosmos Therapeutics INC. | $15.28 | 2023 | Monoferric |
| Avion Pharmaceuticals | $15.13 | 2023 | Balcoltra |
| Lilly USA, LLC | $14.80 | 2024 | Zepbound |
| Therapeuticsmd, INC. | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabrielle Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.